1. Show article details.

    BRIEF-Corcept Therapeutics Appoints Kimberly Park To Board Of Directors

    Reuters – 8:37 AM ET 09/18/2019

    Corcept Therapeutics Inc (CORT): * CORCEPT THERAPEUTICS APPOINTS KIMBERLY PARK TO BOARD OF DIRECTORS. * Corcept Therapeutics Inc (CORT) - PARK WAS GLOBAL VICE PRESIDENT OF CUSTOMER STRATEGY AND INNOVATION AT MERCK (MRK) & CO Source text for Eikon: Further company coverage:

  2. Show article details.

    Corcept Therapeutics Appoints Kimberly Park to Board of Directors

    GlobeNewswire – 8:30 AM ET 09/18/2019

    Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company’s Board of Directors.

  3. Show article details.

    BRIEF-Corcept Therapeutics Announces Allowance Of Additional Patent Covering The Use Of Korlym To Treat Patients With Cushing’S Syndrome

    Reuters – 4:19 PM ET 08/28/2019

    Corcept Therapeutics Inc (CORT): * CORCEPT THERAPEUTICS ANNOUNCES ALLOWANCE OF ADDITIONAL PATENT COVERING THE USE OF KORLYM TO TREAT PATIENTS WITH CUSHING’S SYNDROME. * CORCEPT THERAPEUTICS (CORT)- U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED A NOTICE OF ALLOWANCE FOR A PATENT COVERING ADMINISTRATION OF KORLYM WITH FOOD. * PATENT WILL EXPIRE IN NOVEMBER 2032 Source text for Eikon: Further company coverage:

  4. Show article details.

    Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

    GlobeNewswire – 4:05 PM ET 08/28/2019

    Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food. “This patent covers an important finding of our research – that for optimal effect, Korlym must be taken with food,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.

  5. Show article details.

    BRIEF-Corcept Therapeutics Reports Q2 GAAP Earnings Per Share of $0.17

    Reuters – 5:40 PM ET 08/01/2019

    Corcept Therapeutics Inc (CORT): * CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q2 NON-GAAP EARNINGS PER SHARE $0.25. * Q2 GAAP EARNINGS PER SHARE $0.17. * CORCEPT THERAPEUTICS (CORT) - REPORTS Q2 REVENUE OF $72.3 MILLION. * SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION. * Q2 REVENUE $72.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.9 MILLION.

  6. Show article details.

    BRIEF-Corcept Therapeutics Reports Q2 Non-GAAP Earnings Per Share Of $0.25

    Reuters – 5:27 PM ET 08/01/2019

    Corcept Therapeutics Inc (CORT): * CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q2 NON-GAAP EARNINGS PER SHARE $0.25. * Q2 GAAP EARNINGS PER SHARE $0.17. * SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION. * Q2 REVENUE $72.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.9 MILLION. * SEES Q3 2019 REVENUE $72.3 MILLION.

  7. Show article details.

    Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 08/01/2019

    Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June 30, 2019.

  8. Show article details.

    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

    GlobeNewswire – 4:05 PM ET 07/25/2019

    Corcept Therapeutics Incorporated (CORT) today announced it will report second quarter financial results and provide a corporate update on August 1, 2019. Conference Call Information To participate, dial 1-888-394-8218 from the United States or 1-323-794-2590 internationally approximately ten minutes before the start of the call.

  9. Show article details.

    Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting

    GlobeNewswire – 8:05 AM ET 05/28/2019

    Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel in patients with solid tumors, at the 2...

  10. Show article details.

    Corcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 05/09/2019

    Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its financial results for the quarter ended March 31, 2019.

  11. Show article details.

    Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

    GlobeNewswire – 8:30 AM ET 05/03/2019

    Corcept Therapeutics Incorporated (CORT) today announced it will report first quarter financial results and provide a corporate update on May 9, 2019. Conference Call Information To participate, dial 1-800-347-6311 from the United States or 1-323-994-2132 internationally approximately ten minutes before the start of the call.

  12. Show article details.

    European Medicines Agency Recommends Orphan Drug Designation for Relacorilant to Treat Patients with Cushing’s Syndrome

    GlobeNewswire – 5:05 PM ET 05/02/2019

    Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion recommending the approval of orphan drug de...

Page:

Today's and Upcoming Events

  • Oct
    30

    CORT to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    01

    CORT announced Q2 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.